By assessing how “sticky” tumor cells are, researchers at the University of California San Diego have found a potential way to predict whether a patient’s early-stage breast cancer is likely to spread.
Merus receives FDA accelerated approval to treat NRG1+ cancers
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
December 6, 2024